Mechanisms of Cardiac Hypertrophy

Heart Failure Clinics

Volumn 1, Issue 2, 2005, Pages 263-273

  Selvetella, Giulio ^a   Lembo, Giuseppe ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCINEURIN; CALCINEURIN INHIBITOR; CALSEQUESTRIN; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LOSARTAN; PHOSPHODIESTERASE III; PHOSPHOLAMBAN; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; SYNAPTOPHYSIN; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; HYPOTENSION; MECHANICAL STRESS; NERVE STIMULATION; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 33751184396     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.03.006     Document Type: Review

References (129)

1. Selvetella G., Hirsch E., Notte A., et al. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63 (2004) 373-380
2. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad and the ugly. Annu Rev Physiol 65 (2003) 45-79
3. Tarone G., and Lembo G. Molecular interplay between mechanical and humoral signaling in cardiac hypertrophy. Trends Mol Med 9 (2003) 376-382
4. Epstein N.D., and Davis J.S. Sensing stretch is fundamental. Cell 112 (2003) 147-150
5. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59 (1997) 551-571
6. Russel B., Motlagh D., and Ashley W.W. Form follows function: how muscle shape is regulated by work. J Appl Physiol 88 (2000) 1127-1132
7. Urbanek K., Quaini F., Tasca G., et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci USA 100 (2003) 10440-10445
8. Lips D.J., De Windt L.J., van Kraaij J.W., et al. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24 (2003) 883-896
9. Contard F., Koteliansky V., Marotte F., et al. Specific alterations in the distribution of extracellular matrix components within rat myocardium during the development of pressure overload. Lab Invest 64 (1991) 65-75
10. Molkentin J.D., and Dorn II G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
11. James M.A., Saadeh A.M., and Jones J.V. Wall stress and hypertension. J Cardiovasc Risk 7 (2000) 187-190
12. Morisco C., Sadoshima J., Trimarco B., et al. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol Heart Circ Physiol 284 4 (2003) H1043-H1047
13. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
14. Casale P.N., Devereux R.B., Milner M., et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105 (1986) 173-178
15. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-352
16. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 (2001) 334-341
17. Bolognese L., Dellavesa P., Rossi L., et al. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol 73 (1994) 1-5
18. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 (2001) 1615-1621
19. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 (1998) 48-54
20. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. N Engl J Med 327 14 (1992) 998-1008
21. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left vetricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-350
22. Blade J., Devereux R.B., Herrold E.M., et al. Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am J Cardiol 62 (1988) 246-252
23. Selvetella G., Notte A., Maffei A., et al. Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. Stroke 34 (2003) 1766-1770
24. Kemi O.J., Loennechen J.P., Wisloff U., et al. Intensity-controlled treadmill running in mice: cardiac and skeletal muscle hypertrophy. J Appl Physiol 93 (2002) 1301-1309
25. Ruwlof C., and van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 47 (2000) 23-37
26. Tavi P., Laine M., Weckstrom M., et al. Cardiac mechanotransduction: from sensing to disease and treatment. Trends Pharmacol Sci 22 (2001) 254-260
27. Arber S., Hunter J.J., Ross Jr. J., et al. MLP deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyophathy, and heart failure. Cell 88 (1997) 393-403
28. Shyy J.Y.-J., and Chien S. Role of integrins in endothelial mechanosensing of shear stress. Cir Res 91 (2002) 769-775
29. Belkin A.M., Retta S.F., Pletjushkina O.Y., et al. Muscle β1D integrin reinforces the cytoskeleton-matrix link: modulation of integrin adhesive function by alternative splicing. J Cell Biol 139 (1997) 1583-1595
30. Franchini K.G., Torsoni A.S., Soares P.H., et al. Early activation of the multicomponent signaling complex associated with focal adhesion kinase induced by pressure overload in the rat heart. Circ Res 87 (2000) 558-565
31. Laser M., Willey C.D., Jiang W., et al. Integrin activation and focal complex formation in cardiac hypertrophy. J Biol Chem 275 (2000) 35624-35630
32. Babbitt C.J., Shai S.Y., Harpf A.E., et al. Modulation of integrins and integrin signaling molecules in the pressure-loaded murine ventricle. Histochem Cell Biol 118 (2002) 431-439
33. Aikawa R., Nagai T., Kudoh S., et al. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 39 (2002) 233-238
34. Shai S.Y., Harpf A.E., Babbitt C.J., et al. Cardiac myocyte-specific excision of the β1 integrin gene results in myocardial fibrosis and cardiac failure. Circ Res 90 (2002) 458-464
35. Keller R.S., Shai S.Y., Babbitt C.J., et al. Disruption of integrin function in the murine myocardium leads to perinatal lethality, fibrosis, and abnormal cardiac performance. Am J Pathol 158 (2001) 1079-1090
36. Brancaccio M., Guazzone S., Menini N., et al. Melusin is a new muscle-specific interactor for beta(1) integrin cytoplasmic domain. J Biol Chem 274 (1999) 29282-29288
37. Brancaccio M., Fratta L., Notte A., et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 9 (2003) 68-75
38. De Acetis M., Notte A., Accornero F., et al. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ Res (2005) in press
39. Rapacciuolo A., Esposito G., Caron K., et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure overload cardiac hypertrophy. J Am Coll Card 38 (2001) 876-882
40. Vecchione C., Fratta L., Rizzoni D., et al. Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation 105 (2002) 1700-1707
41. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91 (1994) 10109-10113
42. Rohrer D.K. Physiological consequences of β-adrenergic receptor disruption. J Mol Med 76 (1998) 764-772
43. Dorn II G.W. Adrenergic pathways and left ventricular remodeling. J Card Fail 8 6 Suppl (2002) S370-S373
44. Engelhardt S., Hein L., Wiesmann F., et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96 (1999) 7059-7064
45. Iwase M., Bishop S.P., Uechi M., et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ Res 78 (1996) 517-524
46. Gaudin C., Ishikawa Y., and Wight D.C. Overexpression of Gs alpha protein in the hearts of transgenic mice. J Clin Invest 95 (1995) 1676-1683
47. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
48. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta adrenergic receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
49. Rochman H.A., Chien K.R., Choi D.J., et al. Expression of a beta-adrenergic receptor kinase I inhibitor prevents the development of heart failure in gene-targeted mice. Proc Natl Acad Sci USA 95 (1998) 7000-7005
50. Ungerer M., Bohm M., Elce J.S., et al. Altered expression of beta-adrenergic receptor kinase and beta1 adrenergic receptors in the failing human heart. Circulation 87 (1993) 454-463
51. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study group. N Engl J Med 334 (1996) 1349-1355
52. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
53. Yamazaki T., Komuro I., and Yazaki Y. Role of the rennin-angiotensin system in cardiac hypertrophy. Am J Cardiol 83 (1999) 53H-57H
54. Schunkert H., Dzau V.J., Tang S.S., et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 86 (1990) 1913-1920
55. De Gasparo M., Catt K.J., Inagami T., et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
56. Hein L., Stevens M.E., Barsh G.S., et al. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produce a lethal phenotype associated with myocite hyperplasia and heart block. PNAS USA 94 (1997) 6391-6396
57. Harada K., Komuro I., Shiojima I., et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 97 (1998) 1952-1959
58. Izumi Y., Kim S., Zhan Y., et al. Important role of angiotensin II-mediated c-Jun NH2-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 36 (2000) 511-519
59. Ichihara S., Senbonmatsu T., Price Jr. E., et al. Angiotensin II type receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104 (2001) 346-351
60. Senbonmatsu T., Ichihara S., Price Jr. E., et al. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargment during in vivo pressure overload. J Clin Invest 106 (2000) R25-R29
61. Akishita M., Iwai M., Wu L., et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodelling after aortic banding in mice. Circulation 102 (2000) 1684-1689
62. SOLVD. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
63. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
64. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan heart failure survival study ELITE II. Lancet 355 (2000) 1582-1587
65. Everett A.D., Tufro-McReddie A., Fisher A., et al. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta1 expression. Hypertension 23 (1994) 587-592
66. Jalil J.E., Doering C.W., Janicki J.S., et al. Structural vs contractile protein remodelling and myocardial stiffness in hypertrophied rat left ventricle. J Mol Cell Cardiol 20 (1988) 1179-1187
67. Jalil J.E., Doering C.W., Janicki J.S., et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64 (1989) 1041-1050
68. Ito H., Hiroe M., Hirata Y., et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89 (1994) 2198-2203
69. Arai M., Yoguchi A., Iso T., et al. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 268 (1995) H2084-H2091
70. Wie C.M., Clavell A.L., and Burnett J.C. Atrial and pulmonary endothelin mRNA is increased in a canine model of chronic low cardiac output. Am J Physiol 273 (1997) R838-R844
71. Tonnessen T., Christensen G., Oie E., et al. Increased cardiac expression in endothelin 1 mRNA in ischemic heart failure in rats. Cardiovasc Res 33 (1999) 601-610
72. Wei C.M., Lerman A., Rodeheffer R.J., et al. Endothelin in human congestive heart failure. Circulation 89 (1994) 1580-1586
73. Isoda K., Kamezawa Y., Tada N., et al. Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1α. J Card Fail 7 (2001) 355-364
74. Hirota H., Chen J., Betz U.A., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97 (1999) 189-198
75. Uozumi H., Hiroi Y., Zou Y., et al. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 276 (2001) 23115-23119
76. Schultz J.E., Witt S.A., Nieman M.L., et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 104 (1999) 709-719
77. Pellieux C., Foletti A., Peduto G., et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 108 (2001) 1843-1851
78. Weber K.T., Sun Y., Katwa L.C., et al. Tissue repair and angiotensin II generated at sites of healing. Basic Res Cardiol 92 (1997) 75-78
79. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor solubile receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
80. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
81. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients withmyocarditis and cardiomyopathy. Br Heart J 72 (1994) 561-566
82. Olson E.N., and Williams R.S. Calcineurin signalling and muscle remodelling. Cell 101 (2000) 689-692
83. Zhang W. Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. Cardiovasc Res 53 (2002) 294-303
84. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent trascriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
85. Rothermel B.A., McKinsey T.A., Vega R.B., et al. Myocite-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98 (2001) 3328-3333
86. Sakata Y., Masuyama T., Yamamoto K., et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 102 (2000) 2269-2275
87. Meguro T., Hong C., Asai K., et al. Cyclosporine attenuates pressure overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84 (1999) 735-740
88. Eto Y., Yonekura K., Sonoda M., et al. Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation 101 (2000) 2134-2137
89. Wilkins B.J., Dai Y.S., Bueno O.F., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94 (2004) 110-118
90. Sakata Y., Hoit B.D., Liggett S.B., et al. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 97 (1998) 1488-1495
91. Esposito G., Rapacciuolo A., Naga Prasad S.V., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105 (2002) 85-92
92. Adams J.W., and Brown J.H. G-proteins in growth and apoptosis: lessons from the heart. Oncogene 20 (2001) 1626-1634
93. Sabri A., Wilson B.A., and Steinberg S.F. Dual actions of the Galpha(q) agonist Pasteurella multocida toxin to promote cardiomyocyte hypertrophy and enhance apoptosis susceptibility. Circ Res 90 (2002) 850-857
94. Antos C.L., Frey N., Marx S.O., et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89 (2001) 997-1004
95. Kouchi I., Zolk O., Jockenhovel F., et al. Increase in G(i alpha) protein accompanies progression of post-infarction remodeling in hypertensive cardiomyopathy. Hypertension 36 (2000) 42-47
96. Zou Y., Komuro I., Yamazaki T., et al. Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem 274 14 (1999) 9760-9770
97. Eschenhagen T., Mende U., Nose M., et al. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ Res 70 (1992) 688-696
98. Nishizuka Y. Studies and perspectives of protein kinase C. Science 233 4761 (1986) 305-312
99. Braz J.C., Gregory K., Pathak A., et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nat Med 10 (2004) 248-254
100. Garrington T.P., and Johnson G.L. Organization and regulation of mitogen-activated protein kinase signalling pathways. Curr Opin Cell Biol 11 (1999) 211-218
101. Bueno O.F., De Windt L.J., Tymitz K.M., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19 (2000) 6341-6350
102. Nicol R.L., Frey N., Pearson G., et al. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 20 (2001) 2757-2767
103. Sugden P.H., and Clerk A. 'Stress-responsive' mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen activated protein kinases) in the myocardium. Circ Res 24 (1998) 345-352
104. Clerk A., Michael A., and Sudgen P.H. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein coupled receptor agonists,endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy?. J Cell Biol 142 (1998) 523-535
105. Zhang D., Gaussin V., Taffet G.E., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6 (2000) 556-563
106. Behr T.M., Nerurkar S.S., Nelson A.H., et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104 (2001) 1292-1298
107. Minamino T., Yujiri T., Terada N., et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci USA 99 (2002) 3866-3871
108. Sadoshima J., Montagne O., Wang Q., et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 110 (2002) 271-279
109. Condorelli G., Drusco A., Stassi G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99 (2002) 12333-12338
110. Shioi T., Kang P.M., Douglas P.S., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19 (2000) 2537-2548
111. Matsui T., Li L., Wu J.C., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277 25 (2002) 22896-22901
112. Crackower M.A., Oudit G.Y., Kozieradzki I., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 (2002) 737-749
113. Matsui T., Nagoshi T., and Rosenzweig A. Akt and PI3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2 (2003) 220-223
114. Clerk A., Cole S.M., Cullingford T.E., et al. Regulation of cardiac myocyte cell death. Pharmacol Ther 97 (2003) 223-261
115. Tran H., Brunet A., Griffith E.C., et al. The many forks in FOXO's road. SciSTKE 172 (2003) RE5
116. McMullen J.R., Shioi T., Zhang L., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100 (2003) 12355-12360
117. Frame S., and Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359 (2001) 1-16
118. Zhou P., Sun L.J., Dotsch V., et al. Solution structure of the core NFATC1/DNA complex. Cell 92 (1998) 687-696
119. Haq S., Choukroun G., Kang Z.B., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151 (2000) 117-130
120. Cross D.A., Alessi D.R., Cohen P., et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
121. Antos C.L., McKinsey T.A., Frey N., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99 (2002) 907-912
122. Badorff C., Ruetten H., Mueller S., et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 109 (2002) 373-381
123. Patrucco E., Notte A., Barberis L., et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 (2004) 1-20
124. Esposito G., Santana L.F., Dilly K., et al. Cellular and functional defects in a mouse model of heart failure. Am J Physiol Heart Circ Physiol 279 (2000) H3101-H3112
125. MacLennan D.H., and Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat Reviews 4 (2003) 566-577
126. Minamisawa S., Hoshijima M., Chu G., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99 (1999) 313-322
127. Engelhardt S., Hein L., Dyachenkow V., et al. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation 109 (2004) 1154-1160
128. Sato Y., Kiriazis H., Yatani A., et al. Rescue of contractile parameters and myocite hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem 276 (2001) 9392-9399
129. Freeman K., Lerman I., Kranias E.G., et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 107 (2001) 967-974